BERKELEY, Calif.--(BUSINESS WIRE)--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) clearance from ...
Delayed diagnosis of fibrotic ILD leads to higher mortality rates and shorter overall survival, emphasizing the need for early clinical recognition. Supplemental oxygen therapy in fibrotic ILD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback